International Journal of Clinical Research

Loratinib, as a third-generation inhibitor of anaplastic lymphoma kinase (ALK) tyrosine kinase, has significant therapeutic effects in the treatment of ALK positive non-small cell lung cancer, especially in penetrating the blood-brain barrier and overcoming drug resistance. However, metabolic toxicity seriously affects patients' treatment compliance and quality of life, and its mechanism is not fully understood. Metabolomics can comprehensively reflect the disturbance of drugs on the body's metabolic network by high-throughput detection of small molecule metabolites in biological samples, providing a new perspective for the analysis of toxicity mechanisms. This article combines recent research results, starting from the clinical characteristics of metabolic toxicity related to lorlatinib, and combines the application of metabolomics technology to systematically analyze its core mechanism. It reviews the progress of metabolomics in toxicity monitoring, biomarker screening, and treatment intervention, summarizes research shortcomings, and looks forward to trends, providing theoretical and practical references for precise prevention and control, personalized treatment, and rational drug use.

Loratinib; Metabolomics; Metabolic related toxicity; Mechanism analysis; Therapeutic research; Biomarker